
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Your AI-Trained Oncology Knowledge Connection!


Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.

CancerNetwork® sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for patients with non–small cell lung cancer harboring RET fusions and adequate biomarker testing in the frontline.

Published: June 23rd 2025 | Updated:

Published: July 19th 2021 | Updated:

Published: July 13th 2021 | Updated: